October 28, 2026
Sanofi-Aventis US and a group of drug wholesalers have told a Massachusetts federal judge they have reached a settlement to resolve long-running antitrust litigation alleging that the drugmaker improperly sought to thwart competition for its single-use insulin injector pen.
March 10, 2026
Sanofi-Aventis sparred with drug wholesalers over a Massachusetts federal magistrate judge's pronouncements that the parties should go to trial on claims the pharmaceutical giant used improper insulin device patent listings to anticompetitively protect the blockbuster Lantus insulin pen from competition.
January 05, 2023
Lantus insulin pen buyers are hopping on board the proposed class action-turned direct lawsuit as plaintiffs after counsel for the aggrieved medication buyers realized that the litigation accusing Sanofi-Aventis of anti-competitive behavior wasn't suited to class treatment.
September 14, 2022
A Puerto Rico subsidiary of Sanofi-Aventis cannot be held liable for any alleged antitrust violations by its parent company in a suit accusing the pharmaceutical giant of improperly listing patents for the injector pen of lucrative diabetes drug Lantus, a Boston federal judge ruled Wednesday.
June 14, 2021
Lantus insulin pen buyers can file a new antitrust class action against Sanofi-Aventis in order to name the drugmaker's Puerto Rico subsidiary as a defendant and two more companies as plaintiffs, a Massachusetts federal magistrate has ruled.
March 19, 2021
Lawyers for pharmaceutical giant Sanofi-Aventis U.S. LLC urged a Massachusetts federal judge Friday not to let buyers of its Lantus insulin pen add its "corporate cousin" in Puerto Rico to an antitrust class action, arguing the suit doesn't tie the subsidiary to the overarching alleged anti-competitive conduct.
November 13, 2020
Buyers of Sanofi-Aventis' Lantus insulin pen fought back Friday in Massachusetts federal court against the company's bid to trim their proposed antitrust class action on the grounds the buyer behind the case stopped purchasing the drug partway through the alleged anti-competitive scheme.
October 20, 2020
Sanofi-Aventis is trying to knock out a recently revived antitrust suit accusing it of improperly putting one of its insulin injector patents on an FDA list, which allowed the pharmaceutical company to preemptively sue over up-and-coming generics.
August 26, 2020
Buyers of Sanofi's Lantus insulin treatments told a Massachusetts federal court Wednesday the company has wrongly refused to hand over documents about a number of patents for an injector device after the First Circuit revived their antitrust case based on arguments surrounding a single patent.
February 14, 2020
The First Circuit has revived a proposed class action against Sanofi-Aventis, saying the pharmaceutical company must prove it acted in good faith when it wrongly placed a patent for an insulin injector on an FDA list if it hopes to evade antitrust liability.